Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21557672 | 0.88 | KMT2A (0.42) | KMT2ABRD4LMNAMEN1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10812638 | 0.87 | KMT2A (0.38) | KMT2ALMNAMEN1SMN1; SMN2PKM | |
| SCHEMBL4016019 | 0.82 | KMT2A (0.47) | KMT2AMEN1SMN1; SMN2SLC6A4ALDH1A1 | |
| SCHEMBL10812092 | 0.82 | KMT2A (0.38) | KMT2ABRD4LMNAMEN1SMN1; SMN2 | |
| SCHEMBL10812089 | 0.82 | KMT2A (0.38) | KMT2ABRD4LMNAMEN1SMN1; SMN2 | |
| SCHEMBL16595184 | 0.81 | TSHR (0.35) | LMNASLC6A4SLC6A3 | |
| SCHEMBL19669833 | 0.81 | ALDH1A1 (0.54) | KMT2AALDH1A1KDM4E | |
| SCHEMBL20511752 | 0.81 | KMT2A (0.47) | KMT2ABRD4PKMALDH1A1KDM4E | |
| SCHEMBL30862624 | 0.81 | KMT2A (0.47) | KMT2ABRD4PKMALDH1A1KDM4E | |
| SCHEMBL2464708 | 0.80 | KMT2A (0.48) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332708-A1 | SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS | CYTOKINETICS INC (US) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332708-A1 | SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS | TNNT2, TNNI3, MYLK2 | KMT2A 2745/4885BRD4 1325/4885LMNA 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.